Martin Thorp - In Veritas CFO, Director
| IVME Stock | USD 0.0001 0.00 0.00% |
Director
Mr. Martin Thorp was Chief Financial Officer and a Director of In Veritas Medical Diagnostics Inc. since April 2005. From 2002 through 2005, Mr. Thorp had been involved in various entrepreneurial activities including, the establishment of BizBud Ltd., a private company which provides outsourcing solutions for the small and midsized enterprises across the entire business support spectrum developing a consulting capability for SMEs acting as a consultant to an international corporate finance and strategic advisory boutique serving as strategic advisory nonexecutive board member of Grant Thornton and serving in various short term consulting and interim management positions. From 1996 to 2002, Mr. Thorp served as Global Managing Partner, Corporationrationrate Finance for Arthur Andersen, London and New York. Mr. Thorp graduated with first class honors from the University of Kent at Canterbury in Accounting and Business Finance. Mr. Thorp is a Fellow of the Institute of Chartered Accountants in England and Wales and a member of the Securities Institute . since 2005.
| Age | 72 |
| Tenure | 19 years |
| Address | The Green House, Inverness, United Kingdom, IV2 3Bl |
| Phone | 44 14 6366 7347 |
In Veritas Management Efficiency
The company has return on total asset (ROA) of (6.4797) % which means that it has lost $6.4797 on every $100 spent on assets. This is way below average. In Veritas' management efficiency ratios could be used to measure how well In Veritas manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -244.5. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, In Veritas' Debt To Assets are projected to increase based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 88.52, whereas Net Tangible Assets are forecasted to decline to (6.7 M).Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Jan Bertsch | RBC Bearings Incorporated | 64 | |
| Asad Ghauri | NetSol Technologies | 47 | |
| Stephen Burt | RBC Bearings Incorporated | 55 | |
| Robert Moffatt | RBC Bearings Incorporated | N/A | |
| Dean Foate | RBC Bearings Incorporated | 61 | |
| Curtis Stoelting | RBC Bearings Incorporated | 60 | |
| Rachel Bennun | Radcom | 71 | |
| Malea Farsai | NetSol Technologies | 55 | |
| Anesa Chaibi | RBC Bearings Incorporated | 54 | |
| Thomas Fitzpatrick | Iridium Communications | 66 | |
| Christopher Doerr | RBC Bearings Incorporated | 70 | |
| Michael Hilton | RBC Bearings Incorporated | 65 | |
| Michael Whetten | Datadog | N/A | |
| Zohar Zisapel | Radcom | 75 | |
Management Performance
| Return On Asset | -6.48 |
In Veritas Medical Leadership Team
Elected by the shareholders, the In Veritas' board of directors comprises two types of representatives: In Veritas inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IVME. The board's role is to monitor In Veritas' management team and ensure that shareholders' interests are well served. In Veritas' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, In Veritas' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Martin Thorp, CFO, Director | ||
| Pr Connolly, Director Operations | ||
| Robert Galvin, Head Controller | ||
| G Cooper, CEO Chairman |
IVME Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is In Veritas a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -6.48 | ||||
| Current Valuation | 8.6 K | ||||
| Shares Outstanding | 86.05 M | ||||
| Price To Earning | (0.01) X | ||||
| Price To Sales | 0.14 X | ||||
| EBITDA | (2.07 M) | ||||
| Net Income | (3.67 M) | ||||
| Total Debt | 1.21 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (727.72 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether In Veritas Medical is a strong investment it is important to analyze In Veritas' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact In Veritas' future performance. For an informed investment choice regarding IVME Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in In Veritas Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In Veritas. If investors know IVME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In Veritas listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (6.48) |
The market value of In Veritas Medical is measured differently than its book value, which is the value of IVME that is recorded on the company's balance sheet. Investors also form their own opinion of In Veritas' value that differs from its market value or its book value, called intrinsic value, which is In Veritas' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In Veritas' market value can be influenced by many factors that don't directly affect In Veritas' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In Veritas' value and its price as these two are different measures arrived at by different means. Investors typically determine if In Veritas is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In Veritas' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.